Concepedia

Author

J.M. Piulats Rodriguez

Institut Català d'Oncologia

Also Known As

J M Piulats Rodriguez, J.M. Piulats Rodriguez, J.M. Rodriguez, Jose Maria Piulats Rodriguez

39

Publications

481

Citations

9

H-Index

17

Concepts

All Affiliations

Institut Català d'OncologiaDuran i Reynals HospitalRoyal Marsden HospitalMemorial Sloan Kettering Cancer CenterInstitut Gustave Roussy
JP

About

J.M. Piulats Rodriguez is an author at Institut Català d'Oncologia specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

382

2

Health Sciences

3

3

209

3

Pharmacology

3

3

228

4

Pathology

1

1

73

5

Cancer Cell Biology

1

1

73

J.M. Piulats Rodriguez

×

9

Publications

436

Citations

9

H-Index

YearCitations

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Johann S. de Bono, Jeffrey C. Goh, Kristiina Ojamaa,

Journal of Clinical Oncology

2018

97

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono,

Journal of Clinical Oncology

2012

73

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Oliver Sartor, D.E. Castellano Gauna, Ken Herrmann,

Annals of Oncology

2023

66

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Charles J. Ryan, Matthew R. Smith, Johann S. de Bono,

Journal of Clinical Oncology

2012

58

Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.

J.M. Piulats Rodriguez, María Ochoa de Olza, Manuel Codés,

Journal of Clinical Oncology

2014

54

64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe) (IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)

Joseph J. Sacco, Richard D. Carvajal, Marcus O. Butler,

Annals of Oncology

2020

34

Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

J.M. Piulats Rodriguez, Luis de la Cruz‐Merino, Enrique Espinosa,

Annals of Oncology

2018

33

1772MO Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

Christian Gratzke, Mustafa Özgüroğlu, A. Peer,

Annals of Oncology

2023

11

PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC)

E. Castro Marcos, Nuria Romero-Laorden, J.M. Piulats Rodriguez,

Annals of Oncology

2017

10

Page 1